Need to realign patient-oriented and commercial and academic research
the Responsibility Deal—eg, the need amides in young children. However, Winfred Wang and colleagues1 report for robust, independent, transparent the conclusion that these agents that hydroxycarbamide therapy can scrutiny of commitments made and can now be used in all children now be considered for all very young the beneﬁ ts of a local approach.
with sickle-cell anaemia might be children with sickle-cell anaemia,
Public health sits within a wider premature, since there are still several
socioeconomic system. The project unanswered questions.
First, given the current knowledge is a substantial concern in patients
by a public health team in the region about disease phenotypes, it is not who receive long-term hydroxy-that was prepared to take a risk with clear that the sample size in this carbamide.2 Complications and clinical an unproven concept.4 Critics need to study captured a fair representation eﬃ
cient evidence that of severe disease phenotypes. Thus and colleagues’ trial, some patients
an intervention is meeting planned whether the safety proﬁ le of this were asymptom atic, and the severity outcomes because of short follow-up drug will justify its use in all or a of the underlying disease varied times does not equal evidence that such
select group of young infants with widely between patients. Whether
initiatives do not work. The scepticism sickle-cell anaemia remains an open early initiation of hydroxycarbamide with which projects of this nature have
is beneﬁ cial in asymptomatic patients
Second, and perhaps more as well as those with severe sickle-cell
on preformed conclusions rather than important, is the need to address anaemia remains unknown. objective evidence. A reconsideration the potential use of this drug where We declare that we have no conﬂ icts of interest. of this stance is in order.
it is likely to have the most eﬀ ect on *Yukie Takahashi, Jinichi Mori,
The project to which this letter refers was funded by
global health—ie, settings with a high Masaharu Tsubokura,
the Department of Health East Midlands. We declare
that we have no conﬂ icts of interest.
poor health-care infrastructure. What email@example.com
is the potential eﬀ ect of long-term Tokyo Metropolitan Cancer and Infectious Disease
neutropenia and hyposplenism on Center, Komagome Hospital, 113-8677 Tokyo, Japan
the outcome of patients in settings (YT, JM); and Division of Exploratory Research,
Clinical Sciences Building, Division of Epidemiology
where malaria is endemic and Institute of Medical Science, University of Tokyo,
and Public Health, University of Nottingham,
invasive bacterial infections are highly
Nottingham City Hospital, Nottingham NG5 1PB,
UK (RP, PM, PS); and Department of Health, East
Hydroxycarbamide in very young children with
Midlands, Directorate of Health and Social Care East
sickle cell anaemia: a multicentre, randomised,
controlled trial (BABY HUG). Lancet 2011; 377: 1663–72.
safe blood transfusion cannot be 2 Schultz WH, Ware RE. Malignancy in patients
leadership in England? Lancet 2011;
with sickle cell disease. Am J Hematol 2003;
378: 1060. 74: 249–53.
Department of Health. Public Health Responsibility Deal. http://www.dh.gov.uk/en/
Emphas!s. East Midlands Platform on Obesity,
Need to realign
Physical Activity and Health. http://www.
emphasisnetwork.org.uk/regionalplatform. patient-oriented and
Wanless D. Securing good health for the whole
ernments in the sub-Saharan region commercial and
population: ﬁ nal report—February 2004. http://
We declare that we have no conﬂ icts of interest.
Clinical research is motivated by several factors. Some are more defensible than
Hydroxycarbamide use firstname.lastname@example.org in young children with
Michigan State University, East Lansing, MI 48824,
USA (SKO); Guy’s and St Thomas NHS Foundation Trust, London, UK (BI); and Barts and the London
School of Medicine and Dentistry, London, UK (PT)
studied,1,2 but these are exceptions.
Hydroxycarbamide in very young children with
sickle-cell anaemia: a multicentre, randomised,
controlled trial (BABY HUG). Lancet 2011;
www.thelancet.comVol 378 November 19, 2011 Correspondence
what clinical researchers do and what companies and with input from patients need. I am a researcher; I have
Department of Error Usher AD. Donors continue to hold back support
for research; and I have had multiple new governance strategy would be
from the Global Fund. Lancet 2011;
myeloma for the past decade. A few to bring together all the stakeholders,
378: 471–72—In this World Report (Aug 6), the ﬁ rst line of the seventh paragraph should
years ago I stated publicly that several
have read “Germany, the Global Fund’s fourth
uncertainties I faced at the beginning and ongoing research, produced in-
largest donor after the USA, France, and the
UK, immediately froze its disbursement of $285 million that had been allocated for
10 years later—after a relapse of my Patient advocacy groups in myeloma
2011”. The correction has been made to the
ology” of myeloma studies on hoping to promote better care. With
The Lancet. China’s major health challenge: control
ClinicalTrials.gov. On July 31, 2011, public support they should be in a
of chronic diseases. Lancet 2011; 378: 457—In
a search using the term “multiple strong position to call for a redeﬁ nition
this Editorial (Aug 6), the ﬁ rst sentence of the
myeloma” identiﬁ ed 1384 studies. Of of the research agenda, in the interests
second paragraph should have read “A headline statistic in the report is that reduction of
mortality from cardiovascular disease by only
tive studies. However, in only 58 of be further debated in The Lancet for
1% per year between 2010 and 2040 will save
these studies was overall survival an many other areas of clinical research in
the country a staggering US$10·7 trillion.” This correction has been made to the online version
I thank Mariangela Taricco, Iain Chalmers,
head-to-head comparison of diﬀ erent Gianni Ciccone, Michele Cavo, Nicola Magrini, and
Mandell DS, Levy SE, Schultz RT. Eﬀ ectiveness of
drugs or strategies. Meanwhile, Roberto Satolli for useful comments in preparation of
intensive autism programmes—Authors’ reply.
this letter. I declare that I have no conﬂ icts of interest.
Lancet 2010; 375: 723—In this
Correspondence (Feb 27, 2010), the second
and gene-expression proﬁ ling will lead Alessandro Liberati
paragraph should have read: “With regard to
other randomised trials of ABA, space limitations prevented a more thorough
oma,4 and pharmaceutical companies Università di Modena and Reggio Emilia, Modena,
listing of references within that review;
avoid research that might show that Italy; and Agenzia Sanitaria e Sociale Regionale,
Vismara’s article is Rogers’s 1998 review3 of
Buckley BS, Grant A, Glazener CMA. Case study:
ﬁ ve studies preceding the ﬁ ve referenced in
a patient-clinician collaboration that identiﬁ ed
her 2008 article. We originally classiﬁ ed these
and prioritized evidence gaps and stimulated
as randomised trials, but accept that they in
research involvement. J Clin Epidemiol 2011;
published online Aug 3. DOI:10.1016/j.
correction has been made to the online version
Stewart RJ, Caird J, Oliver K, Oliver S. Patients’
and clinicians’ research priorities. Health ExpectMalfertheiner P, Bazzoli F, Delchier JC, et al.
Helicobacter pylori eradication with a capsule
Liberati A. An unﬁ nished trip through the uncertainties. BMJ 2004; 328: 531–32. containing bismuth subcitrate potassium, metronidazole, and tetracycline given with
Russel SJ, Rajkumar SV. Multiple myeloma and the road for personalised medicine.
omeprazole versus clarithromycin-based triple Lancet Oncol 2011; 12: 617–19. therapy: a randomised, open-label,
and academic—which lead them to 5 Liberati A, Moja PL, Trotta F, Traversa G.
non-inferiority, phase 3 trial. Lancet 2011;
Feasibility and challenge of independent
377: 905–13—In this Article (March 12), the
research on drugs: the Italian Medicines
fourth sentence of the third paragraph in the
Agency (AIFA) experience. Eur J Clin Invest
Procedures section (p 906) should have read:
2010; 40: 69–86.
“In the 7-day standard regimen, one capsule of
omeprazole, two of amoxicillin, and one of
clarithromycin were taken twice daily (before morning and evening meals).” This correction
has been made to the online version as of
Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815–25—In this Series paper (Aug 27), the x-axes of parts A–D of ﬁ gure 5 were
labelled incorrectly. The label should have
been x100 000, and the values should have
been diﬀ erent for the USA (10, 20, 30) and the UK (2, 4, 6). These corrections have been made
to the online version as of Nov 18, 2011.
www.thelancet.comVol 378 November 19, 2011
For Immediate Release: January 31, 2013 The Atlantic City Police Department Special Investigations Section, along with the New Jersey Treasury Department Office of Criminal Investigation SIU and the New Jersey Division of Consumer Affairs Enforcement Bureau recently completed an investigation into several local convenience stores for various criminal offenses including the sale of pres
Panafcort® Consumer Medicine Information (CMI) What is in this leaflet Do not take Panafcort after the expiry date (EXP) printed on the Do not take it if the bottle shows signs of having been tampered Do not take this medicine to Ask your doctor if you have any complaints questions about why Panafcort has been prescribed for you. instructed you